TRK-INHIBITING COMPOUND Russian patent published in 2018 - IPC C07D401/12 C07D403/12 C07D401/14 C07D403/14 C07D471/04 C07D487/04 A61K31/444 A61K31/506 A61K31/519 A61K31/4439 A61P29/00 

FIELD: medicine.

SUBSTANCE: invention relates to a compound of general formula (I) wherein the Cy₁ cycle is phenyl, cyclohexyl, pyridinyl, pyrazolyl, triazolyl, thienyl, tetrahydrofuranyl; Cy₂ cycle is a pyridine ring, a pyrimidine ring, a pyrazolopyrimidine ring, an imidazopyridazine ring, an imidazopyridine ring, a pyrrolopyridine ring, an imidazopyrazine ring or a pyrazolopyridine ring; R₁ represents a halogen; C_1-6-alkyl group optionally substituted with 1 to 3 substituents selected from the group consisting of (i) halogen and (ii) hydroxy or C_2-6-alkynyl group; phenyl optionally substituted with one or two R₅ groups or indanyl; A 5-6 membered monocyclic heterocycle optionally substituted with one or two R₅ groups or dihydrobenzofuran; -S(O)_m1-R₆; -SO₂NR₇R₈; -OR₁₄; R₅ represents a halogen; cyano group; or C_1-3-alkyl group optionally substituted with 1 to 3 substituents selected from the group consisting of (i) halogen, (ii) hydroxy groups and (iii) oxo groups; when there are two groups R₅, the group R₅ independently may be the same or different; R₆, R₇, R₈, R₁₄ or R₂₀ respectively and independently represent (1) a hydrogen atom or (2) C_1-6-alkyl group optionally substituted by (ii) a hydroxy group; R₂ represents a halogen; C_1-6-alkyl group optionally substituted with (i) a halogen or (ii) a hydroxy group; C_3-6-cycloalkyl group; C_1-6-alkoxy group; -NR₂₈R₂₉; pyrrolidinyl, azetidinyl; or -O-(oxetanyl); R₂₈ and R₂₉ respectively and independently represent a hydrogen atom or C_1-6-alkyl group optionally substituted by (ii) a hydroxy group; A₁ and A₂ respectively and are independently =CR₃- or =N-; A₃, A₄, A₅ and A₆ respectively and are independently =CR₄-; R₃ and R₄ respectively and independently represent a hydrogen atom; m1 is an integer from 0 to 2; p is an integer from 0 to 4; q is an integer from 0 to 2; r represents 0; provided that when p, q and r are respectively an integer of 2 or more, group R₁, R₂ and R₃ respectively, and independently may be the same or different, or a pharmaceutically acceptable salt thereof. Invention also relates to a pharmaceutical composition having an inhibitory activity against Trk based on a compound of formula (I).

(I).

EFFECT: technical result consists in that new compounds have been obtained that can be used in medicine for the treatment of pain or cancer.

18 cl, 8 tbl, 23 ex